|
 |
|
|||||||
|
|||||||||
Correspondence to:
Xian-cheng Jiang
Phospholipid transfer protein gene knock-out (Pltp KO) mice have defective transfer of very low density lipoprotein (VLDL) phospholipids into high density lipoprotein (HDL) and markedly decreased HDL levels (Jiang et al. 1999. J. Clin. Invest. 103: 907;–914). These animals also accumulated VLDL- and LDL-sized lipoproteins on a high saturated fat diet. The goals of this study were to further characterize the abnormal lipoproteins of Pltp KO mice and to determine the mechanisms responsible for low HDL levels. A lipoprotein fraction enriched in lamellar structures was isolated from the low density lipoprotein (LDL) region and was shown to be phospholipid- and free cholesterol-rich and to have apoA-IV (55%) and apoE (25%) as major apolipoproteins. The lamellar lipoproteins accumulating in these mice probably represent surface material derived from triglyceride-rich lipoproteins (TRL). The HDL was found to be protein-rich (primarily apoA-I) and specifically depleted in phosphatidylcholine (PC) (28% in wild-type mice (WT) vs. 15% in Pltp KO mice, P < 0.001). Unexpectedly, turnover studies using autologous HDL revealed a profound 4-fold increase in the catabolism of HDL protein and cholesteryl ester in Pltp KO mice compared to wild-type, with minor differences in synthesis rates. In contrast, injection of WT mouse HDL into Pltp KO mice showed only a 2-fold increase in fractional catabolism. Reminiscent of the defect in Tangier disease, the failure of transfer of PC from TRL into the HDL fraction results in dramatic hypercatabolism of HDL.
These results suggest that defective phospholipid transfer from TRL into HDL, arising from decreased lipolysis or decreased PLTP activity, could lead to hypoalphalipoproteinemia characterized by hypercatabolism of HDL protein.—Qin, S., K. Kawano, C. Bruce, M. Lin, C. Bisgaier, A. R. Tall, and X-c. Jiang. Phospholipid transfer protein gene knock-out mice have low high density lipoprotein levels, due to hypercatabolism, and accumulate apoA-IV-rich lamellar lipoproteins. J. Lipid Res. 2000. 41: 269;–276.
Supplementary key words:
HDL, lipoproteins, apolipoproteins, phospholipids, fractional catabolic rate
Plasma PLTP circulates bound to HDL and mediates both net transfer and exchange of phospholipids among different lipoproteins. In vitro evidence has suggested that PLTP plays an important role in lipoprotein interconversion and remodeling. During lipolysis of VLDL, partially purified PLTP affected both the transfer and exchange of phospholipid between these particles and HDL \n (1). The PLTP gene belongs to a family that includes cholesteryl ester transfer protein, lipopolysaccharide binding protein, and bactericidal permeability increasing protein (2) PLTP can also cause conversion of HDL3 to large and smaller particles in a time- and concentration-dependent fashion (3). Furthermore, PLTP activity on HDL can modulate the activities of LCAT and CETP in vitro (4) (5). There is also accumulating in vivo evidence that PLTP has a central role in lipoprotein metabolism. In PLTP transgenic mice, PLTP overexpression increases the influx of phospholipid, and secondarily of cholesterol, into HDL, leading to an increase in potentially antiatherogenic preß-HDL particles (6) (7) (8).
Recently, we have developed PLTP gene knock-out (Pltp KO) mice. Our initial characterization of these animals indicates that: 1) PLTP is the major agent facilitating transfer of VLDL phospholipid into HDL, 2) reduced plasma PLTP activity causes markedly decreased HDL lipid and apolipoprotein, demonstrating the importance of transfer of surface components of triglyceride-rich lipoproteins in the maintenance of HDL levels, and 3) on a high saturated fat diet, PLTP deficiency causes accumulation of lamellar lipoproteins, which are isolated in the IDL/LDL region by FPLC and in HDL by ultracentrifugation (9). In the previous study the centrifugally isolated HDL fraction contained both spherical HDL and lamellar lipoproteins, and the lamellar lipoprotein fraction isolated by FPLC was contaminated with VLDL and LDL (9). In the present study we have characterized purified HDL and lamellar lipoprotein fractions, and then carried out lipoprotein turnover studies. Our results indicate that inhibition of phospholipid transfer from apoB-containing particles to HDL in Pltp KO mice leads to changes in HDL composition and altered metabolic stability of these particles.
Animals and diets used in this study
Lipids and lipoproteins measurements
Isolation of phospholipid/free cholesterol/apoA-IV-rich particles
Western blot of apoA-IV, apoA-I, and apoE
In vivo turnover studies
Electron Microscopy
Statistical analysis
Previously we showed that, on a high saturated fat diet, there was an increase in phospholipid (210%), free cholesterol (66%), and cholesteryl ester (40%) without change in apoB levels in the centrifugally isolated VLDL/LDL of Pltp KO mice (9). The excessive accumulation of phospholipids and free cholesterol suggested the presence of lamellar lipoproteins in the non-HDL fraction and this was confirmed by negative stain electron microscopy (9). When isolated by ultracentrifugation, the lamellar particles were found in the HDL density range (9). Taking advantage of their physical characteristics, i.e, HDL density and IDL/LDL size (9), we isolated these lipoproteins in relatively pure form, using a combination of preparative ultracentrifugation followed by FPLC. Compositional analysis showed that these particles are composed of PC (50 ± 3%), SM (11 ± 1%), free cholesterol (17 ± 2%), cholesteryl ester (11 ± 2%), and protein (9 ± 1%). The protein composition was determined by SDS 4;–20% gradient-PAGE run under reducing conditions. A major band (about 55% of total protein) with the size of apoA-IV and two minor bands (25 and 15%) with the sizes of apoE and apoA-I were visible ( Fig 1, left panel). Western blotting with specific antibodies confirmed that these proteins were indeed apoA-IV, apoE, and apoA-I (Fig 1, right panel). To confirm that apoA-IV was enriched in these particles, we carried out Western blot analysis of FPLC fractions of the plasma of Pltp KO and WT mice, using anti-apoA-IV polyclonal antibody. This revealed an apoA-IV-containing lipoprotein particle accumulating in the IDL/LDL size-range fractions in FPLC ( Fig 2), where lamellar particles were observed (9).
Using negative-stain electron microscopy, these apoA-IV-rich particles appeared as a mixture of spherical and lamellar structures with a diameter of 40;–50 nm ( Fig 3). Discoidal structures, some in stacks, were visible edge-on. The thickness of most of the stacked disks was 4;–5 nm, although some were thicker, suggesting collapsed vesicles. Other round structures may represent vesicles or discs en face or spherical lipoprotein. However, the low content of neutral lipid in their fraction suggests a paucity of neutral lipid core-containing particles.
To characterize the metabolism of these apoA-IV-rich particles, they were labeled with 125I and injected into Pltp KO mice (n = 5). We found that the fractional catabolic rate (FCR) for the protein associated with these particles was 0.20 ± 0.02 pools/h and the half life was about 45 min ( Fig 4). This was similar to the FCR of HDL protein in the Pltp KO mice (see below).
To determine the HDL composition, we pooled plasma from 5 Pltp KO and 5 wild-type (WT) mice, respectively, and took the HDL region from the FPLC profile, then we spun up the HDL at density 1.21 g/ml. The results from three independent experiments showed that 58 ± 6% of the HDL mass of Pltp KO mice is protein, 42 ± 3% of the particle mass is lipid, while HDL particles from WT mice contain 41 ± 3% protein and 59 ± 5% lipid ( Table 1). As shown in Fig 5, the major HDL protein was apoA-I in both WT and Pltp KO mice. Among the lipids, it is notable that the HDL of Pltp KO mice is specifically deficient in phosphatidylcholine (PC), while the percentage composition of other lipids is not changed (Table 1). We also measured lipid and protein composition of the centifugally isolated VLDL and LDL of Pltp KO mice (i.e. without lamellar lipoproteins) and found that both lipoproteins are specifically depleted in sphingomyelin (SM) (Table 1). Thus, the PC/SM ratio was higher in VLDL and LDL and lower in HDL of PLTP KO animals compared to WT mice.
Our previous work revealed that in Pltp KO mice there is a marked 85% reduction in apoA-I levels (9). To understand the mechanism for this dramatic change, we carried out HDL turnover studies in PLTP KO and WT mice, using both autologous and heterologous HDL. We initially hypothesized that in Pltp KO mice the inhibition of phospholipid and apolipoprotein transfer from triglyceride-rich lipoprotein (TRL) particles into HDL would result in a predominant HDL synthetic defect.
In autologous turnover studies, Pltp KO and WT mice were injected with their own HDL, doubly labeled by [3H]CE incorporation and protein iodination with 125I. In this experiment, the FCRs of [3H]CE-HDL, 125I-labeled HDL and 125I-labeled apoA-I in Pltp KO mice were about four times greater than for WT mice ( Fig 6, Table 2). Based on the FCR, body weight, and pool size, we calculated the production rates of HDL-CE and HDL-apoA-I for both WT and Pltp KO mice ( Table 3), and found the difference to be insignificant.
In the heterologous turnover studies, HDL from WT mice was isolated and doubly labeled by incorporating [3H]CE into its lipids and radioiodination of its proteins with 125I. When this doubly labeled HDL from WT mice was injected into WT and Pltp KO mice, we found that the FCRs for both the [3H]CE and 125I-labeled apolipoprotein in Pltp KO were about twice those in WT mice ( Fig 7, Table 4). We isolated 125I-labeled apolipoproteins in HDL from mouse plasma at each time point by ultracentrifugation and SDS-PAGE. The proportion of apolipoproteins among the particles was determined by quantitative scanning using a Phosphorimager (Molecular Dynamics). The FCRs of all apolipoproteins showed similar changes (Table 4).
In this study we have extended our characterization of the plasma lipoprotein changes in Pltp KO mice. The major novel finding was that low HDL in these animals arises from dramatically increased catabolism of HDL protein, possibly related to a decrease in PC content of HDL. Also, lamellar lipoproteins accumulating in these animals were found to be enriched in apoA-IV and apoE. Such particles could influence atherogenesis in these mice.
Low HDL in PLTP-deficient mice was found to be due primarily to a marked increase in catabolism of HDL particles, with similarly increased catabolism for both HDL proteins and CE. The increased catabolism is unlikely to be solely secondary to a decrease in HDL pool size as HDL from WT mice was catabolized more slowly than HDL from Pltp KO mice when injected into Pltp KO mice (Table 4). Also, apoA-I KO mice do not show increased HDL catabolism despite a profoundly reduced HDL pool size (13). This indicates that a defect in the HDL per se is at least partly responsible for its increased catabolism. Compositional analysis indicated that the HDL of Pltp KO mice was enriched in protein and specifically depleted in PC. These changes presumably reflect the defect in the transfer of PC from TRL into HDL (9). The abnormal composition of HDL, and possible associated changes in physical properties, likely lead to hypercatabolism of apoA-I and HDL particles. An intriguing question is the mechanism of increased catabolism of these PC-depleted HDL particles.
These findings are reminiscent of the defect in Tangier disease, where extremely low HDL levels result from increased catabolism, independent of HDL pool size (14). In Tangier disease, a defect in the ATP-binding cassette transporter, ABC1, appears to cause a defect in transfer of cellular phospholipids and cholesterol onto apoA-I (15) (16) (17). This may interfere with the interaction of apoA-I with the plasma membrane (18), and could also result in defective formation of nascent HDL in the liver. As pointed out by Young and Fielding (19), the defect in Tangier disease is more severe than in PLTP deficiency. This could indicate that the ABC1 molecule is involved in an earlier step during the biogenesis of HDL, forming nascent HDL particles which then develop into mature HDL particles as a result of PLTP and LCAT activities ( Fig 8).
There are some interesting similarities in the HDL changes of Pltp KO mice and those seen in humans or mice with abetalipoproteinemia (20) (21) (22). In human abetalipoproteinemia, HDL levels are moderately reduced, and the HDL has an increased SM/PC ratio (20). Moreover, low HDL reflects, in part, increased catabolism of HDL protein (23). In mice with liver-specific knock-out of microsomal triglyceride transfer protein, HDL cholesterol levels are reduced by about 50% (21). These similarities to the PLTP deficiency state suggest that the major source of phospholipids transferred by PLTP is derived from apoB-containing lipoproteins. However, PLTP is highly expressed in several peripheral tissues such as lung and adipose tissue and PLTP has been reported to promote cellular phospholipid efflux to HDL (24). This could represent an additional source of phospholipids transferred into HDL by PLTP.
Human subjects with low HDL levels typically have increased catabolism of HDL protein. A significant subset of these individuals have mutations in ABC1 without having features of classic Tangier disease (15). The present results suggest that hypoalphalipoproteinemia associated with increased catabolism of HDL protein could also result from defective transfer of phospholipids from TRL into HDL. Theoretically, this could result from defects in the PLTP gene (though none have yet been found) or from defective lipolysis. There are several common LPL variants that are associated with hypertriglyceridemia and decreased HDL levels (25). Defective phospholipid transfer secondary to the lipolytic defect could cause low HDL due to increased catabolism of HDL particles, as in the PLTP-deficient mouse. This is a mechanism distinct from the currently held view that increased core lipid exchange mediated by CETP leads to low HDL in hypertriglyceridemia (26).
Once freed of lamellar particles, the VLDL and LDL were found to be specifically deficient in SM (Table 1). This is interesting because nascent VLDL isolated from the rat Golgi is deficient in SM (27). Thus, it is possible that SM enters the lipoprotein system predominantly through HDL (e.g., from the interaction of apoA-I with plasma membrane (18)), and is transferred to VLDL and LDL by PLTP. SM may be an important component of atherogenic lipoproteins related to its interaction with sphingomyelinase in the arterial wall (28).
Another striking feature of the PLTP-deficient mice fed a high saturated fat diet was the accumulation of lamellar lipoproteins, enriched in PC, free cholesterol, apoA-IV, and apoE. These particles presumably represent surface material derived from TRL that fails to be incorporated into HDL as a result of PLTP deficiency. It is notable that these particles are only present in mice fed a high saturated fat, coconut oil-based diet, and are not seen in mice fed chow (9) or a milk fat-based Western diet (unpublished). The enrichment with apoA-IV could indicate a specific role of this apolipoprotein in the phospholipid transfer process, as suggested by some previous experiments (29). It is more likely, however, that apoA-IV is attracted to the surface material by mass action, or that the apoA-IV particles are surface components detached from triglyceride-rich particles that have lost core volume after lipoprotein lipase activity. Recently, Bergeron et al. (30) have demonstrated the accumulation of lamellar lipoproteins enriched with apoA-IV as a major constituent in compound Hl KO/Apoe KO mice. These workers described signet ring structures which we did not observe in our studies, even though the lamellar fraction did contain significant amounts of neutral lipid. Bergeron et al.(30) speculated that these structures might represent TRL remnants that circulated for an extended period allowing depletion of core lipid by selective uptake in the liver. Interestingly, the accumulation of these particles in Hl KO/Apoe KO mice was associated with an anti-atherogenic effect. Thus, it will be of interest to determine whether the lamellar lipoprotein fraction influences atherogenesis in the Pltp KO mice.
This work was supported by National Institutes of Health grant HL-54591.
Manuscript received September 28, 1999; and in revised form November 23, 1999
Abbreviations:
apo, apolipoprotein; FPLC, fast protein liquid chromatography; KO, knock-out; PLTP, phospholipid transfer protein; Pltp, phospholipid transfer protein gene; TRL, triglyceride-rich lipoproteins; HDL, high density lipoprotein; IDL, intermediate density lipoprotein; LDL, low density lipoprotein; VLDL, very low density lipoprotein; FCR, fractional catabolic rate; SM, sphingomyelin; CE, cholesteryl oleyl ether
Copyright © 2000 by Lipid Research, Inc.
Original Article
Phospholipid transfer protein gene knock-out mice have low high density lipoprotein levels, due to hypercatabolism, and accumulate apoA-IV-rich lamellar lipoproteins
Shucun Qina,
Koichi Kawanoa,
Can Brucea,
Min Lina,
Charles Bisgaierb,
Alan R. Talla, and
Xian-cheng Jianga
a Division of Molecular Medicine, Department of Medicine, Columbia University, New York NY 10032
b Esperion Therapeutics, Inc., Ann Arbor, MI 48108
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
Materials and Methods
RESULTS
DISCUSSION
REFERENCES
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
Materials and Methods
RESULTS
DISCUSSION
REFERENCES
Materials and Methods
TOP
ABSTRACT
INTRODUCTION
Materials and Methods
RESULTS
DISCUSSION
REFERENCES
All phenotypic characterizations were performed with wild-type (WT) and Pltp KO homozygous littermates after backcrossing to C57BL/6. The N4 generation (93% C57BL/6 and 7% 129 genetic background), 10;–12 weeks old, was used for analysis. Female mice were used in all the studies. Two diets were used: Purina Rodent Chow (no. 5001) with or without 20% hydrogenated coconut oil and 0.15% cholesterol (Research Diets Inc. New Brunswick, NJ, USA).
Fasting plasma was collected for lipoprotein isolation and lipid measurement. Total cholesterol, free cholesterol, and phospholipids in plasma and lipoproteins were assayed by enzymatic methods (Wako Pure Chemical Industries Ltd., Osaka, Japan). Cholesteryl ester concentration was calculated by subtracting the free cholesterol from total plasma cholesterol.
The PL/apoA-IV-rich particles were isolated from the plasma of Pltp KO mice fed the high saturated fat diet by ultracentrifugation followed by fast protein liquid chromatography (FPLC). Briefly, 500 µl of pooled Pltp KO mouse plasma (n = 5) was adjusted to density 1.063 g/ml and placed in a 5-ml tube; 4.5 ml of d 1.063 g/ml NaBr solution was overlaid on the plasma. The tube was sealed and spun at 98,000 rpm for 4 h in an Optima TL ultracentrifuge (Beckman, Brea, CA). The tube was sliced, the top 0.8 ml solution (VLDL and LDL) was discarded, and the bottom 4.2 ml solution was adjusted to density 1.21 g/ml. The tube was spun at 98,000 rpm for 12 h and then sliced. The top 0.8 ml of solution, which contains apoA-IV-rich particles and HDL, was desalted and concentrated to a volume of 220 µl with a Centricon 30 (Pharmacia). The final solution was loaded onto a Superose 6 column (Pharmacia) and eluted with 0.1 M Tris-HCl (pH 7.5) at a constant flow rate of 0.35 ml/min. The apoA-IV-rich particles were located in the LDL size-range fractions (fractions 16;–19).
To analyze the apolipoprotein composition, the isolated apoA-IV-rich particles (20 µl, corresponding to 50 µl plasma) were run on 4;–20% gradient SDS-PAGE gels under reducing conditions. The proteins were then transferred to a nitrocellulose membrane (Bio-Rad Laboratories) and immunoblotted using a polyclonal anti-mouse apoA-I antibody, a polyclonal anti-mouse apoE antibody (Biodesign), and a polyclonal anti-rat apoA-IV antibody that cross-reacts with mouse apoA-IV. The signal was detected by chemiluminescence using the ECL kit (Amersham). The proportion of apolipoproteins among the particles was determined by quantitative scanning using a Phosphorimager (Molecular Dynamics). Each apolipoprotein band was individually quantitated by a customized box that isolated one band from another.
Except where otherwise noted, HDL was purified first by ultracentrifugation and then by gel filtration to exclude the apoA-IV-containing lipoprotein species described here. Isolated HDL was labeled with 125I (Pierce Chemical Company, Rockford, IL), and [3H]cholesteryl oleyl ether (CE) (NEN, Boston, MA) as described previously (10). For heterologous lipoprotein studies, Pltp KO and WT mice were injected intravenously in the femoral vein with WT HDL labeled with 125I and [3H]cholesteryl oleyl ether (1.1 x 106 and 0.95 x 106 cpm, respectively). For autologous lipoprotein studies, Pltp KO and WT mice were injected intraveously with their own HDL labeled with 125I or [3H]CE (3 x 106 and 2 x 106 cpm, respectively). After injection, blood (70 µl) was taken from the tail vein at 0.17, 0.5, 1, 2, 4, 8, and 24 h for determination of radioactivity. The fractional catabolic rates (FCR) for protein and lipid were calculated from the decay curves of 125I and [3H]CE radioactivity in whole plasma according to the Matthews method (11). The production rates were calculated by multiplying the FCR by the plasma pool and dividing by the body weight (12).
Negative-stain electron microscopy was done as described (9).
Differences between groups were tested by Student's t test. Data are presented as mean ± SD.
RESULTS
TOP
ABSTRACT
INTRODUCTION
Materials and Methods
RESULTS
DISCUSSION
REFERENCES
View larger version (76K):
[in a new window]
Figure 1.
Protein composition of lamellar lipoprotein fraction. Particles were isolated by ultracentrifugation followed by FPLC. Proteins were separated by SDS, 4;–20% gradient polyacrylamide gel electropheresis under reducing conditions, and immunoblotted with a polyclonal anti-rat-apoA-IV antibody which can cross-react with mouse apoA-IV (A), a polyclonal anti-mouse apoE antibody (B), or a polyclonal anti-mouse apoA-I antibody (C), respectively.
View larger version (32K):
[in a new window]
Figure 2.
ApoA-IV-rich particles accumulate in Pltp KO mouse plasma on a high saturated fat diet. A 200-µl aliquot of pooled plasma (from 6 animals) was fractionated on a Superose 6B column (1 ml/fraction). The indicated fractions were concentrated 10-fold, and 20 µl of solution was analyzed by Western blotting. A) Immunoblot of apoA-IV in each FPLC fraction; B) phospholipid distribution in each FPLC fraction.
View larger version (130K):
[in a new window]
Figure 3.
Negative-stain electron microscopy of apoA-IV-rich particles purified from Pltp KO mouse plasma, pooled from 5 animals. Two representative views are shown.
View larger version (14K):
[in a new window]
Figure 4.
Radioactivity decay curves for 125I-labeled apoA-IV-rich particles. Pltp KO mice (n = 5) were injected intravenously with 125I-labeled apoA-IV-rich particles, then 70 µl of blood was collected from the tail vein at the indicated time points; 35 µl of plasma was used for radioactivity measurement.
View larger version (66K):
[in a new window]
Figure 5.
SDS-PAGE analysis of apolipoproteins from WT and Pltp KO mouse HDL. HDL was isolated by FPLC followed by ultracentrifugation at d 1.21 g/ml. HDL containing equal amounts of cholesterol was loaded on a 4;–20% SDS-polyacrylamide gradient gel and the apolipoproteins were stained by Coomassie Brilliant Blue.
View this table:
[in a new window]
Table 1.
Lipid and protein composition in Pltp KO and wild-type (WT) mice lipoproteins
View larger version (16K):
[in a new window]
Figure 6.
Plasma fractional catabolic rates for 125I- and [3H]CE-labeled HDL in mice (autologous HDL). Pltp KO (n = 5) and WT mice (n = 5) were injected intraveously (femoral vein) with their own HDL labeled with 125I and [3H]CE. Blood (70 µl) was collected from the tail vein at 10 min, 0.5, 1, 2, 4, 8, and 24 h for determination of radioactivity. The values are mean ± SD.
View this table:
[in a new window]
Table 2.
Plasma fractional catabolic rates for 125I-labeled and [3H]-cholesteryl oleyl ether-labeled HDL in mice (autologous)
View this table:
[in a new window]
Table 3.
HDL-CE and HDL-apoA-I production rates in wild-type (WT) and Pltp KO mice (autologous)
View larger version (15K):
[in a new window]
Figure 7.
Plasma fractional catabolic rates for 125I- and [3H]CE-labeled HDL from WT mice (heterologous HDL). Pltp KO (n = 5) and WT mice (n = 5) were injected intravenously (femoral vein) with WT HDL labeled with 125I and [3H]CE. Blood (70 µl) was collected from the tail vein at 10 min, 0.5, 1, 2, 4, 8, and 24 h for determination of radioactivity.The values are mean ± SD.
View this table:
[in a new window]
Table 4.
Plasma fractional catabolic rates for 125I-labeled and [3H]cholesteryl oleyl ether-labeled HDL in mice (heterologous)
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
Materials and Methods
RESULTS
DISCUSSION
REFERENCES
View larger version (15K):
[in a new window]
Figure 8.
A hypothetical scheme for the role of PLTP in the formation of mature HDL particles. In step 1, phospholipids and free cholesterol, effluxed from cells as a result of ABC1 activity, combine with apoA-I, generating nascent HDL. In step 2, nascent HDL acquires additional phospholipids and free cholesterol as a result of transfer from triglyceride-rich lipoprotein (TRL) by PLTP, and is acted on by LCAT, generating mature HDL. PC, phosphatidycholine; FC, free cholesterol; ABC1, ATP-binding cassette transporter 1; LCAT, lecithin:cholesterol acyltransferase; TRL, triglyceride-rich lipoproteins; AI, apolipoprotein A-I.
ACKNOWLEDGMENTS
REFERENCES
TOP
ABSTRACT
INTRODUCTION
Materials and Methods
RESULTS
DISCUSSION
REFERENCES
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Schlitt, S. Blankenberg, C. Bickel, K. J. Lackner, G. H. Heine, M. Buerke, K. Werdan, L. Maegdefessel, U. Raaz, H. J. Rupprecht, et al. PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene Study J. Lipid Res., April 1, 2009; 50(4): 723 - 729. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lyly, S. K. Marjavaara, A. Kyttala, K. Uusi-Rauva, K. Luiro, O. Kopra, L. O. Martinez, K. Tanhuanpaa, N. Kalkkinen, A. Suomalainen, et al. Deficiency of the INCL protein Ppt1 results in changes in ectopic F1-ATP synthase and altered cholesterol metabolism Hum. Mol. Genet., May 15, 2008; 17(10): 1406 - 1417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Shelly, L. Royer, T. Sand, H. Jensen, and Y. Luo Phospholipid transfer protein deficiency ameliorates diet-induced hypercholesterolemia and inflammation in mice J. Lipid Res., April 1, 2008; 49(4): 773 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. T. Valenta, J. J. Bulgrien, D. J. Bonnet, and L. K. Curtiss Macrophage PLTP is atheroprotective in LDLr-deficient mice with systemic PLTP deficiency J. Lipid Res., January 1, 2008; 49(1): 24 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Kiss, N. Kavaslar, K.-i. Okuhira, M. W. Freeman, S. Walter, R. W. Milne, R. McPherson, and Y. L. Marcel Genetic Etiology of Isolated Low HDL Syndrome: Incidence and Heterogeneity of Efflux Defects Arterioscler. Thromb. Vasc. Biol., May 1, 2007; 27(5): 1139 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Sarov-Blat, R. S. Kiss, B. Haidar, N. Kavaslar, M. Jaye, M. Bertiaux, K. Steplewski, M. R. Hurle, D. Sprecher, R. McPherson, et al. Predominance of a Proinflammatory Phenotype in Monocyte-Derived Macrophages From Subjects With Low Plasma HDL-Cholesterol Arterioscler. Thromb. Vasc. Biol., May 1, 2007; 27(5): 1115 - 1122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Vikstedt, D. Ye, J. Metso, R. B. Hildebrand, T. J.C. Van Berkel, C. Ehnholm, M. Jauhiainen, and M. Van Eck Macrophage Phospholipid Transfer Protein Contributes Significantly to Total Plasma Phospholipid Transfer Activity and Its Deficiency Leads to Diminished Atherosclerotic Lesion Development Arterioscler. Thromb. Vasc. Biol., March 1, 2007; 27(3): 578 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Haidar, R. S. Kiss, L. Sarov-Blat, R. Brunet, C. Harder, R. McPherson, and Y. L. Marcel Cathepsin D, a Lysosomal Protease, Regulates ABCA1-mediated Lipid Efflux J. Biol. Chem., December 29, 2006; 281(52): 39971 - 39981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Klein, V. Deckert, M. Schneider, F. Dutrillaux, A. Hammann, A. Athias, N. Le Guern, J.-P. Pais de Barros, C. Desrumaux, D. Masson, et al. {alpha}-Tocopherol Modulates Phosphatidylserine Externalization in Erythrocytes: Relevance in Phospholipid Transfer Protein-Deficient Mice Arterioscler. Thromb. Vasc. Biol., September 1, 2006; 26(9): 2160 - 2167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lee-Rueckert, R. Vikstedt, J. Metso, C. Ehnholm, P. T. Kovanen, and M. Jauhiainen Absence of endogenous phospholipid transfer protein impairs ABCA1-dependent efflux of cholesterol from macrophage foam cells J. Lipid Res., August 1, 2006; 47(8): 1725 - 1732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Dallinga-Thie, A. van Tol, H. Hattori, P. C.N. Rensen, E. J.G. Sijbrands, and for the Diabetes Atorvastatin Lipid Intervention ( Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin: a role for apolipoprotein e? Diabetes, May 1, 2006; 55(5): 1491 - 1496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ji, G. F. Watts, A. G. Johnson, D. C. Chan, E. M. M. Ooi, K.-A. Rye, A. P. Serone, and P. H. R. Barrett High-Density Lipoprotein (HDL) Transport in the Metabolic Syndrome: Application of a New Model for HDL Particle Kinetics J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 973 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nilsson and R.-D. Duan Absorption and lipoprotein transport of sphingomyelin J. Lipid Res., January 1, 2006; 47(1): 154 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Wu and D. E. Cohen Phosphatidylcholine transfer protein regulates size and hepatic uptake of high-density lipoproteins Am J Physiol Gastrointest Liver Physiol, December 1, 2005; 289(6): G1067 - G1074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Janis, S. Siggins, E. Tahvanainen, R. Vikstedt, K. Silander, J. Metso, A. Aromaa, M.-R. Taskinen, V. M. Olkkonen, M. Jauhiainen, et al. Active and low-active forms of serum phospholipid transfer protein in a normal Finnish population sample J. Lipid Res., December 1, 2004; 45(12): 2303 - 2309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Brown, A. Gauthier, R. J. Parks, R. McPherson, D. L. Sparks, J. R. Schultz, and Z. Yao Severe Hypoalphalipoproteinemia in Mice Expressing Human Hepatic Lipase Deficient in Binding to Heparan Sulfate Proteoglycan J. Biol. Chem., October 8, 2004; 279(41): 42403 - 42409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Yan, M. Navab, C. Bruce, A. M. Fogelman, and X.-C. Jiang PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity J. Lipid Res., October 1, 2004; 45(10): 1852 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Webb, M. C. de Beer, B. F. Asztalos, N. Whitaker, D. R. van der Westhuyzen, and F. C. de Beer Remodeling of HDL remnants generated by scavenger receptor class B type I J. Lipid Res., September 1, 2004; 45(9): 1666 - 1673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lie, R. de Crom, T. van Gent, R. van Haperen, L. Scheek, F. Sadeghi-Niaraki, and A. van Tol Elevation of plasma phospholipid transfer protein increases the risk of atherosclerosis despite lower apolipoprotein B-containing lipoproteins J. Lipid Res., May 1, 2004; 45(5): 805 - 811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Siggins, M. Karkkainen, J. Tenhunen, J. Metso, E. Tahvanainen, V. M. Olkkonen, M. Jauhiainen, and C. Ehnholm Quantitation of the active and low-active forms of human plasma phospholipid transfer protein by ELISA J. Lipid Res., February 1, 2004; 45(2): 387 - 395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Siggins, M. Jauhiainen, V. M. Olkkonen, J. Tenhunen, and C. Ehnholm PLTP secreted by HepG2 cells resembles the high-activity PLTP form in human plasma J. Lipid Res., September 1, 2003; 44(9): 1698 - 1704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. P. Yang, D. Yan, C. Qiao, R. J. Liu, J.-G. Chen, J. Li, M. Schneider, L. Lagrost, X. Xiao, and X.-C. Jiang Increased Atherosclerotic Lesions in ApoE Mice With Plasma Phospholipid Transfer Protein Overexpression Arterioscler. Thromb. Vasc. Biol., September 1, 2003; 23(9): 1601 - 1607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Hudgins, T. S. Parker, D. M. Levine, B. R. Gordon, S. D. Saal, X.-c. Jiang, C. E. Seidman, J. D. Tremaroli, J. Lai, and A. L. Rubin A single intravenous dose of endotoxin rapidly alters serum lipoproteins and lipid transfer proteins in normal volunteers J. Lipid Res., August 1, 2003; 44(8): 1489 - 1498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Soro, M. Jauhiainen, C. Ehnholm, and M.-R. Taskinen Determinants of low HDL levels in familial combined hyperlipidemia J. Lipid Res., August 1, 2003; 44(8): 1536 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Vuletic, L.-W. Jin, S. M. Marcovina, E. R. Peskind, T. Moller, and J. J. Albers Widespread distribution of PLTP in human CNS: evidence for PLTP synthesis by glia and neurons, and increased levels in Alzheimer's disease J. Lipid Res., June 1, 2003; 44(6): 1113 - 1123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Mardones, A. Pilon, M. Bouly, D. Duran, T. Nishimoto, H. Arai, K. F. Kozarsky, M. Altayo, J. F. Miquel, G. Luc, et al. Fibrates Down-regulate Hepatic Scavenger Receptor Class B Type I Protein Expression in Mice J. Biol. Chem., February 28, 2003; 278(10): 7884 - 7890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. van Haperen, A. van Tol, T. van Gent, L. Scheek, P. Visser, A. van der Kamp, F. Grosveld, and R. de Crom Increased Risk of Atherosclerosis by Elevated Plasma Levels of Phospholipid Transfer Protein J. Biol. Chem., December 6, 2002; 277(50): 48938 - 48943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lie, R. de Crom, T. van Gent, R. van Haperen, L. Scheek, I. Lankhuizen, and A. van Tol Elevation of plasma phospholipid transfer protein in transgenic mice increases VLDL secretion J. Lipid Res., November 1, 2002; 43(11): 1875 - 1880. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. R. Hopkins, Y. Huang, J. G. McGuire, and R. E. Pitas Evidence for differential effects of apoE3 and apoE4 on HDL metabolism J. Lipid Res., November 1, 2002; 43(11): 1881 - 1889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Cao, T. P. Beyer, X. P. Yang, R. J. Schmidt, Y. Zhang, W. R. Bensch, R. F. Kauffman, H. Gao, T. P. Ryan, Y. Liang, et al. Phospholipid Transfer Protein Is Regulated by Liver X Receptors in Vivo J. Biol. Chem., October 11, 2002; 277(42): 39561 - 39565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Murdoch, M. C. Carr, H. Kennedy, J. D. Brunzell, and J. J. Albers Selective and independent associations of phospholipid transfer protein and hepatic lipase with the LDL subfraction distribution J. Lipid Res., August 1, 2002; 43(8): 1256 - 1263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Gander, P. Eller, S. Kaser, I. Theurl, D. Walter, T. Sauper, A. Ritsch, J. R. Patsch, and B. Foger Molecular characterization of rabbit phospholipid transfer protein: choroid plexus and ependyma synthesize high levels of phospholipid transfer protein J. Lipid Res., April 1, 2002; 43(4): 636 - 645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Murdoch, G. Wolfbauer, H. Kennedy, S. M. Marcovina, M. C. Carr, and J. J. Albers Differences in reactivity of antibodies to active versus inactive PLTP significantly impacts PLTP measurement J. Lipid Res., February 1, 2002; 43(2): 281 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhou and A. Nilsson Sources of eicosanoid precursor fatty acid pools in tissues J. Lipid Res., October 1, 2001; 42(10): 1521 - 1542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Gotto Jr Low High-Density Lipoprotein Cholesterol as a Risk Factor in Coronary Heart Disease : A Working Group Report Circulation, May 1, 2001; 103(17): 2213 - 2218. [Full Text] [PDF]
|
|
|
|
|
|
H. M. Colhoun, L. M. Scheek, M. B. Rubens, T. Van Gent, S. R. Underwood, J. H. Fuller, and A. Van Tol Lipid Transfer Protein Activities in Type 1 Diabetic Patients Without Renal Failure and Nondiabetic Control Subjects and Their Association With Coronary Artery Calcification Diabetes, March 1, 2001; 50(3): 652 - 659. [Abstract] [Full Text]
|
|
|
|
|
|
A. R. Tall, X.-c. Jiang, Y. Luo, and D. Silver 1999 George Lyman Duff Memorial Lecture : Lipid Transfer Proteins, HDL Metabolism, and Atherogenesis Arterioscler. Thromb. Vasc. Biol., May 1, 2000; 20(5): 1185 - 1188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kawano, S.-C. Qin, M. Lin, A. R. Tall, and X.-c. Jiang Cholesteryl Ester Transfer Protein and Phospholipid Transfer Protein Have Nonoverlapping Functions in Vivo J. Biol. Chem., September 15, 2000; 275(38): 29477 - 29481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L. Urizar, D. H. Dowhan, and D. D. Moore The Farnesoid X-activated Receptor Mediates Bile Acid Activation of Phospholipid Transfer Protein Gene Expression J. Biol. Chem., December 8, 2000; 275(50): 39313 - 39317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. McManus, B. R. Scott, V. Franklin, D. L. Sparks, and Y. L. Marcel Proteolytic Degradation and Impaired Secretion of an Apolipoprotein A-I Mutant Associated with Dominantly Inherited Hypoalphalipoproteinemia J. Biol. Chem., June 8, 2001; 276(24): 21292 - 21302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Scott, D. C. McManus, V. Franklin, A. G. McKenzie, T. Neville, D. L. Sparks, and Y. L. Marcel The N-terminal Globular Domain and the First Class A Amphipathic Helix of Apolipoprotein A-I Are Important for Lecithin:Cholesterol Acyltransferase Activation and the Maturation of High Density Lipoprotein in Vivo J. Biol. Chem., December 21, 2001; 276(52): 48716 - 48724. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |